CTAG1A
Chr Xcancer/testis antigen 1A
Also known as: CT6.1, ESO1, LAGE-2, LAGE2A, NY-ESO-1
The protein encoded by this gene is a tumor cell antigen found in various types of cancers, which makes it a good candidate for a cancer vaccine. This gene is also highly expressed in normal ovary and testis tissues. An identical copy of this gene is found on the same chromosome. [provided by RefSeq, Dec 2015]
Population Genetics & Constraint
Constraint data not available from gnomAD.
ClinVar Variant Classifications
130 submitted variants in ClinVar
Classification Summary
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories· variant type breakdown unavailable
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | — | — | — | — | 114 |
Likely Pathogenic | — | — | — | — | 4 |
VUS | — | — | — | — | 12 |
Likely Benign | — | — | — | — | 0 |
Benign | — | — | — | — | 0 |
| Total | — | 130 | |||
Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
CTAG1A · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
External Resources
Links to major genomics databases and tools
Variant Interpretation
Population Databases
Gene Resources
Expert Curation
No open access results found
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
RECRUITINGDose Escalation Study of Immunomodulatory Nanoparticles
ACTIVE NOT RECRUITINGMaster Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
ACTIVE NOT RECRUITINGRare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
NOT YET RECRUITINGStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
ACTIVE NOT RECRUITINGTCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
NOT YET RECRUITINGMulti-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
RECRUITINGAdministration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
ACTIVE NOT RECRUITINGGene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITINGGene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITINGExosomeDx in MRI-negative Men With High PSA
NOT YET RECRUITINGA Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
NOT YET RECRUITINGExternal Resources
Links to major genomics databases and tools